Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...
Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous polyposis, ...
Biodexa Pharmaceuticals reports updates from the MAGIC-1 study on MTX110 for recurrent glioblastoma. MTX110 has also demonstrated potential in treating diffuse midline glioma, a rare brain cancer ...
The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...
European shares were higher today. The eurozone's STOXX 600 gained 0.58%, Germany's DAX 40 rose 0.57% and France's CAC 40 ...